Wednesday, April 29, 2026 Dr. Goss is a Fellow of the Royal College of Physicians and Surgeons of Canada, Professor Emeritus, Department of Medicine, University of Ottawa and a Senior Clinician Scientist, Ottawa Hospital Research Institute. He is the past Head and Chair of the Division of Medical Oncology at the University of Ottawa and the past Director of Clinical and Translational Research at The Ottawa Hospital Cancer Centre. A founding member of the Canadian Association of Medical Oncologists, he served as President from 1999-2001. From 2007-2019 he was the Chair of the Thoracic Oncology Site Committee, Canadian Cancer Trials Group, a member of the US Co-operative Group Chairs Committee (Lung) and member of the Thoracic Malignancy Steering Committee, NCI (US), National Institute of Health. Since 1999, he has been a member of the International Association for the Study of Lung Cancer (IASLC) and chaired the Publications Committee from 2014-2016. He has published widely in his areas of interest, namely cancer drug development and thoracic oncology, with over 400 publications including publications in New England Journal of Medicine, Nature Medicine, Journal of Clinical Oncology (JCO) and Lancet Oncology. He has served on multiple journal editorial boards including JCO, and on of several scientific boards of international conferences. His research continues to be supported by multiple peer-reviewed grants. His contribution to patient care acknowledged by the receipt of “Guardian Angel Awards” from his patients and his academic work by national and international commendations and awards, including the Korean Society for the Study of Lung Cancer Visiting Professor Award; Certificate of Appreciation, the National Institute of Health, National Cancer Institute (US); and the “Lifetime Achievement Award” from the Canadian Lung Cancer Conference. "I am grateful and privileged to receive 2026 CCTG Founder’s Award – the Dr. Joseph Pater Excellence in Clinical Trials Research Award. Dr Pater through leadership, innovation and hard work established the Canadian Cancer Trials Group (CCTG) which has become a gold standard and world leader in Cancer Clinical Trials. Under his guidance, CCTG embarked on an expanding spectrum of activity, from first-in-human studies to randomized phase 3 trials supported by state of the art translational and health services research.This has led to seminal trials which have improved the standard of cancer patient care and outcomes in Canada and internationally. Furthermore, he has mentored a generation of physician researchers, many of whom have become prominent leaders in their fields of endeavor."
